Percutaneous treatments of primary aneurysmal bone cysts: systematic review and meta-analysis

Eur J Orthop Surg Traumatol. 2021 Oct;31(7):1287-1295. doi: 10.1007/s00590-021-02893-6. Epub 2021 Feb 7.

Abstract

Purpose: To systematically review the literature to determine recurrence rates of percutaneous treatments for primary aneurysmal bone cysts (ABC).

Methods: Search strategies were performed in the following databases: PubMed, SCIELO, LILACS and BVS, using terms in English, Spanish and Portuguese (PROSPERO Registration Number: CRD42020170340). Longitudinal studies, either observational or clinical trials, with at least five patients and with a mean of 18 months of follow-up were included. Studies had to use any type of percutaneous treatments and report the recurrence rates of primary ABC treatment. Studies selection, data extraction and risk of bias assessment were performed independently by two researchers. A global meta-analysis was carried out to assess the proportion of recurrence. Studies were categorized into two subgroups: selective arterial embolization and sclerotherapy.

Results: Thirteen studies were included in the present study. The average success rate of percutaneous treatments for ABC was 91.11%, with a total of 37 lesions recurrences in the 416 patients. The sex ratio was 1:1. The subgroup of sclerotherapies presented a lower proportion of recurrence. The proportion of recurrence in the subgroup of selective arterial embolization was 19% (95%IC 12.11-27.54) and that of sclerotherapies was 6% (95%IC 3.65-9.19).

Conclusions: Both percutaneous treatments for ABC are effective, showing a lower rate of recurrence. Sclerotherapy treatments seem to be promising, but further clinical trials must be conducted with a longer follow-up.

Keywords: Bone cysts; Embolization; Recurrence; Sclerotherapy.

Publication types

  • Meta-Analysis
  • Review
  • Systematic Review

MeSH terms

  • Bone Cysts, Aneurysmal* / diagnostic imaging
  • Bone Cysts, Aneurysmal* / therapy
  • Embolization, Therapeutic*
  • Humans
  • Neoplasm Recurrence, Local
  • Sclerotherapy
  • Treatment Outcome

Grants and funding